

Scientific publications based on Quality registry:

Publications in year 2017:

- A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries. *Clin. Infect. Dis.*
Kjaer, S.K., Nygård, M., Dillner, J., Brooke Marshall, J., Radley, D., Li, M., Munk, C., Hansen, B.T., Sigurdardottir, L.G., Hortlund, M., Tryggvadottir, L., Joshi, A., Das, R., Saah, A.J., 2017. A
- Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study. *J. Infect. Dis.* 216, 336–344.
Baussano, I., Lazzarato, F., Ronco, G., Lehtinen, M., Dillner, J., Franceschi, S., 2017.
- Effect of naturally acquired type-specific serum antibodies against human papillomavirus type 16 infection. *J. Clin. Virol.* 90, 64–69
Triglav, T., Artemchuk, H., Oštrbenk, A., Elfström, K.M., Faust, H., Poljak, M., Dillner, J., 2017.
- Effectiveness of cervical screening after age 60 years according to screening history: Nationwide cohort study in Sweden. *PLoS Med.* 14, e1002414.
Wang, J., Andrae, B., Sundström, K., Ploner, A., Ström, P., Elfström, K.M., Dillner, J., Sparén, P., 2017.
- Human Papillomavirus (HPV) Prevalence in Male Adolescents 4 Years After HPV-16/18 Vaccination. *J. Infect. Dis.* 216, 966–968.
Lehtinen, T., Söderlund-Strand, A., Petäjä, T., Eriksson, T., Jokiranta, S., Natunen, K., Dillner, J., Lehtinen, M., 2017.
- Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56-60. *BMJ Open* 7, e014788.
Lamin, H., Eklund, C., Elfström, K.M., Carlsten-Thor, A., Hortlund, M., Elfgren, K., Törnberg, S., Dillner, J., 2017.
- Registry follow-up for 17 million person-years of a nationwide maternity cohort. *Cancer Med* 6, 3060–3064.
Lehtinen, M., Surcel, H.-M., Natunen, K., Pukkala, E., Dillner, J., 2017b. Cancer
- Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials. *BMJ Open* 7, e015867.
Lehtinen, M., Lagheden, C., Luostarinen, T., Eriksson, T., Apter, D., Harjula, K., Kuortti, M., Natunen, K., Palmroth, J., Petäjä, T., Pukkala, E., Siitari-Mattila, M., Struyf, F., Nieminen, P., Paavonen, J., Dubin, G., Dillner, J., 2017a.

- Vaccination protects against invasive HPV-associated cancers. *Int. J. Cancer*.
Luostarinen, T., Apter, D., Dillner, J., Eriksson, T., Harjula, K., Natunen, K., Paavonen, J., Pukkala, E., Lehtinen, M., 2017.
- Risk of high-grade lesions after atypical glandular cells in cervical screening: a population-based cohort study. *BMJ Open* 7, e017070.
Norman, I., Hjerpe, A., Dillner, J., 2017.
- Socio-economic and demographic determinants of participation in the Swedish cervical screening program: a population-based case-control study.
Broberg G, Wang J, Östberg A L, Adolfsson A., Nemes S, Sparén P, Strander B.
- Suppressive art associated with effective treatment of cervical precancer. Nordic HIV & Hepatitis Conference i Stockholm, 27-29 september 2017
Carlander C, Wagner P, van Beirs A, Yilmaz A, Elfgren K, Dillner J, Sönnernborg A, Sparén P
- The economic burden of human papillomavirus-related precancers and cancers in Sweden. *PLoS ONE* 12, e0179520.
Östensson, E., Silfverschiöld, M., Greiff, L., Ascitto, C., Wennerberg, J., Lydryp, M.-L., Håkansson, U., Sparén, P., Borgfeldt, C., 2017.